European Commission approves Roche's Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancerGlobeNewsWire • 12/23/20
Roche's faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindnessGlobeNewsWire • 12/21/20
Genentech's Faricimab Meets Primary Endpoint and Shows Strong Durability Across Two Global Phase III Studies for Diabetic Macular Edema, a Leading Cause of BlindnessBusiness Wire • 12/21/20
Roche launches cobas PIK3CA Mutation Test for patients with advanced or metastatic breast cancer in countries accepting the CE markGlobeNewsWire • 12/15/20
FDA approves Roche's OCREVUS® (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive multiple sclerosisGlobeNewsWire • 12/14/20
FDA Approves Genentech's Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple SclerosisBusiness Wire • 12/14/20
Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patientsGlobeNewsWire • 12/11/20
Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020GlobeNewsWire • 12/10/20
Roche partners with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trialsGlobeNewsWire • 12/09/20
Roche presents new data from its bispecific antibody portfolio across a range of blood cancersGlobeNewsWire • 12/08/20
New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphomaGlobeNewsWire • 12/07/20
New follow-up phase III data reinforce the long-term benefit of Roche's Hemlibra for people with haemophilia AGlobeNewsWire • 12/07/20
Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemiaGlobeNewsWire • 12/05/20
Genentech Announces New Data Reinforcing the Long-Term Benefit of Venclexta-Based Combination for People With Relapsed or Refractory Chronic Lymphocytic LeukemiaBusiness Wire • 12/05/20